188 related articles for article (PubMed ID: 16883559)
1. Increase of doxorubicin sensitivity for folate receptor positive cells when given as the prodrug N-(phenylacetyl) doxorubicin in combination with folate-conjugated PGA.
Zhang Q; Xiang G; Zhang Y; Yang K; Fan W; Lin J; Zeng F; Wu J
J Pharm Sci; 2006 Oct; 95(10):2266-75. PubMed ID: 16883559
[TBL] [Abstract][Full Text] [Related]
2. [Anticancer activity of N-(phenylacetyl) doxorubicin combined with folate-targeted PGA].
Zhang Q; Xiang GY; Long N; Lin JL; Zeng FB
Yao Xue Xue Bao; 2005 Nov; 40(11):1046-50. PubMed ID: 16499093
[TBL] [Abstract][Full Text] [Related]
3. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
Lu JY; Lowe DA; Kennedy MD; Low PS
J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814
[TBL] [Abstract][Full Text] [Related]
4. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
5. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.
Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH
Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative.
Abu Ajaj K; El-Abadla N; Welker P; Azab S; Zeisig R; Fichtner I; Kratz F
Eur J Cancer; 2012 Sep; 48(13):2054-65. PubMed ID: 21937219
[TBL] [Abstract][Full Text] [Related]
7. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate.
Yoo HS; Park TG
J Control Release; 2004 Nov; 100(2):247-56. PubMed ID: 15544872
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a folate receptor-targeted immunoglobulin G-doxorubicin conjugate.
Yang T; Xu L; Li B; Li W; Ma X; Fan L; Lee RJ; Xu C; Xiang G
Int J Nanomedicine; 2017; 12():2505-2515. PubMed ID: 28408821
[TBL] [Abstract][Full Text] [Related]
9. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model.
Pan XQ; Wang H; Lee RJ
Pharm Res; 2003 Mar; 20(3):417-22. PubMed ID: 12669962
[TBL] [Abstract][Full Text] [Related]
11. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
12. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
13. Carboxymethyl-β-cyclodextrin conjugated nanoparticles facilitate therapy for folate receptor-positive tumor with the mediation of folic acid.
Su C; Li H; Shi Y; Wang G; Liu L; Zhao L; Su R
Int J Pharm; 2014 Oct; 474(1-2):202-11. PubMed ID: 25149123
[TBL] [Abstract][Full Text] [Related]
14. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate.
Vrudhula VM; Senter PD; Fischer KJ; Wallace PM
J Med Chem; 1993 Apr; 36(7):919-23. PubMed ID: 8464046
[TBL] [Abstract][Full Text] [Related]
15. Targeted magnetic liposomes loaded with doxorubicin.
Pradhan P; Banerjee R; Bahadur D; Koch C; Mykhaylyk O; Plank C
Methods Mol Biol; 2010; 605():279-93. PubMed ID: 20072888
[TBL] [Abstract][Full Text] [Related]
16. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
[TBL] [Abstract][Full Text] [Related]
17. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y
Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031
[TBL] [Abstract][Full Text] [Related]
18. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
19. Folate mediated self-assembled phytosterol-alginate nanoparticles for targeted intracellular anticancer drug delivery.
Wang J; Wang M; Zheng M; Guo Q; Wang Y; Wang H; Xie X; Huang F; Gong R
Colloids Surf B Biointerfaces; 2015 May; 129():63-70. PubMed ID: 25829128
[TBL] [Abstract][Full Text] [Related]
20. Comparative preclinical activity of the folate-targeted Vinca alkaloid conjugates EC140 and EC145.
Leamon CP; Reddy JA; Vlahov IR; Westrick E; Parker N; Nicoson JS; Vetzel M
Int J Cancer; 2007 Oct; 121(7):1585-92. PubMed ID: 17551919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
